Ironwood taps AstraZeneca as China partner for linaclotide in risk-sharing deal
This article was originally published in Scrip
Ironwood Pharmaceuticals is on something of a roll with its irritable bowel syndrome (IBS) and constipation drug linaclotide, having received US FDA approval of the first-in-class guanylate cyclase-C agonist in August and then a positive EU approval recommendation last month.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.